Last reviewed · How we verify
RXC004
At a glance
| Generic name | RXC004 |
|---|---|
| Also known as | zamaporvint |
| Sponsor | Redx Pharma Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC) (PHASE2)
- A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) (PHASE2)
- Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RXC004 CI brief — competitive landscape report
- RXC004 updates RSS · CI watch RSS
- Redx Pharma Ltd portfolio CI